Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Researchers at Case Western Reserve school of Medicine looked at nearly one million patients in the U.S. with Type 2 diabetes ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Ozempic, a drug initially intended for type 2 diabetes treatment, is gaining popularity for weight loss and reducing ...

While Ozempic has been shown to lead to weight loss as a side effect, it's not without risks. According to the Cleveland ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Researchers previously found that Type 2 diabetes patients could lower their risk for ten obesity-related cancers by taking Ozempic instead of insulin. REUTERS Earlier this year, researchers found ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...